Clinical Trials Using Rimiducid
Clinical trials are research studies that involve people. The clinical trials on this list are studying Rimiducid. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Location: 9 locations
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide and Pembrolizumab in Treating Patients with Malignant Pleural Disease
This phase I / II trial studies the side effects and best dose of mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes and to see how well it works with or without cyclophosphamide and pembrolizumab in treating patients with a malignant disease found in the thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity (pleura), including malignant pleural mesothelioma, or previously treated non-small cell lung cancer or breast cancer that has spread to the pleura. Placing a gene that has been created in the laboratory into white blood cells (lymphocytes) may help the body build an immune response to kill tumor cells expressing the protein mesothelin. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes with or without cyclophosphamide may be a better treatment for malignant pleural disease.
Location: 7 locations
Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (pancreatic, stomach, or prostate) expressing high levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to recognize and target the PSCA tumor marker on cancer cells.
Location: 3 locations
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Background: Multiple myeloma is a blood cancer that is usually incurable. T cells are part of the immune system. Researchers think changing a person s T cells to recognize their cancer could help the person s body kill tumor cells. This is a new approach that uses a patient s own cells to target multiple myeloma. Objective: To see if giving anti-SLAM7 CAR T cells with a stop switch to people with multiple myeloma is safe andto see if adding a gene to stop T-cell activity can limit toxicity of this therapy. Eligibility: People ages 18-73 with multiple myeloma for which prior standard treatment has not worked Design: Participants will be screened with: - Medical history - Physical exam - Blood, urine, and heart tests - Bone marrow samples: A needle inserted into the participant s bone will remove marrow. - Imaging scans: Participants will lie in a machine that takes pictures of the body. Participants will have apheresis. They will receive a catheter or central line: A plastic tube will be inserted into a chest or arm vein. Blood will be removed and the T cells separated. The rest of the blood will be returned to the participant. The T cells will be manipulated in the lab. Participants will get chemotherapy through the central line for 3 days. Participants will receive the manipulated T cells through the central line. They will stay in the hospital at least 9 days. Participants will have follow-up visits 2 weeks then 1, 2, 3, 4, 6, 9, and 12 months after the infusion. They will then have visits every 6 months for 3 years. Then they will be contacted once per year for 15 years. All visits will include blood tests, and 3 visits will include bone marrow biopsies....
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Umbilical Cord Blood Immune Cells and Chemotherapy in Treating Participants with Recurrent or Refractory CD19 Positive Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma
This phase I / II trial studies the side effects and best dose of allogeneic iC9 / CAR.19 / IL15-transduced cord blood (CB) natural killer (NK) cells (umbilical cord blood immune cells) when given together with chemotherapy, and to see how well they work in treating participants with CD19 positive acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma that has come back or does not respond to treatment. iC9 / CAR.19 / IL15-transduced CB-NK cells are genetically changed immune cells that may help improve the disease. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving iC9 / CAR.19 / IL15-transduced CB-NK cells and chemotherapy may work better in treating participants with acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma.
Location: M D Anderson Cancer Center, Houston, Texas
Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
This phase I trial studies the side effect of autologous inducible caspase 9 chimeric antigen receptor targeting CD19 antigen (iC9-CAR19) T cells in treating patients with acute lymphoblastic leukemia that has come back (recurrent) or does not respond to treatment (refractory). IC9-CAR19 T cells combines antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances and by stopping them from growing. T cells are special infection fighting blood cells that can kill other cells, including cancer cells or cells that are infected.
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Location: 2 locations